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[571 ABSTRACT 
An antisense oligonucleotide of 10 to 35 nucleotides in 
length that can hybridize with a region of the a1 subunit of 
the SA-Cat channel gene DNA or mRNA is provided, 
together with pharmaceutical compositions containing and 
methods utilizing such antisense oligonucleotide. 
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VOLTAGE-GATED CALCIUM CHANNEL 
AND ANTISENSE OLIGONUCLEOTIDES 
THERETO 
This invention was made with Government support 
under NASA grant NAG 2-791 awarded by the National 
Aeronautics and Space Administration and NIH grants AR 
39561 and GM 34399 awarded by the National Institute of 
Health. The Government has certain rights in the invention. 
BACKGROUND OF THE INVENTION 
This invention relates to a voltage-gated calcium channel 
that stimulates bone formation in osteoblasts and mediates 
arterial tone in endothelial cells. More specifically, it relates 
to the gene for the voltage-gated calcium channel, antisense 
oligonucleotides useful for regulating the expression of the 
voltage-gated calcium channel gene and processes for the 
use of the antisense oligonucleotides to inhibit expression of 
the voltage-gated calcium channel, to inhibit bone 
formation, to mediate vascular blood pressure, and as an 
analytical tool useful for the development of strategies for 
responding to the bone loss caused by osteoporosis. 
It has been known for a century that mechanical strain- 
whether resulting from physiological exercise or artificial 
means-increases bone formation and remodeling activity 
resulting in increased bone mass. Similarly, endothelial cells 
subjected to mechanical forces via fluid shear and vessel 
expansion have been shown to undergo increased cell pro- 
liferation and vasoactive secretions. Prior to the present 
invention, however, the precise molecular mechanism for 
enhancing the amount of bone deposited at the vector of 
force applied in osteoblasts and for increasing endothelial 
cell proliferation and vasoactive secretion, has remained 
unclear. 
Voltage-gated calcium channels are members of a super- 
family of cation channels, which also includes channels for 
Na+, K+ and divalent cations, i.e., Ca”. Calcium channels 
are responsible for the rapid entry of calcium into excitable 
cells upon membrane depolarization and are essential for 
excitation-contraction coupling in muscle, and the propaga- 
tion of action potentials and neurotransmitter release in 
neurons. In addition, calcium channels regulate stimulus- 
secretion coupling during hormone release in endocrine 
glands. Much less is known about the roles of these calcium 
channels in other types of nonexcitable tissues. 
Calcium channels may be sub-classified according to their 
electrophysiological behavior and pharmacological sensi- 
tivities. L-type calcium channels are defined pharmacologi- 
cally by their sensitivity to three classes of calcium channel 
blockers, the phenylalkylamines, benzothiazepines and 
dihydropyridines. L-type calcium channels are multi- 
component proteins made up of five subunits: al, a2, 6, y, 
and 0. The properties of calcium channels are largely 
conferred by the a1 subunit, which forms the actual pore site 
for the channel. The structure of the a1 subunit has been 
elucidated. It consists of four homologous repeats (I-IV) 
consisting of six membrane-spanning domains (Sl-S6). The 
dihydropyridine receptor for the L-type channel is located 
on the carboxyl end of the a1 unit of the protein just beyond 
the S6 domain of the IV region. 
Although common features of the structure of calcium 
channels have been established, variations in this structure 
have also been identified. At least six classes of calcium 
channel a1 subunit genes have now been identified, three of 
which are members of the dihydropyridine-sensitive L-type 
subfamily, including skeletal muscle (CaChl), cardiac 
2 
muscle (CaCh2) and neuroendocrine (CaCh3) isoforms. Still 
greater diversity is generated by alternative splicing. 
Osteoblasts, the cells responsible for bone growth, have 
voltage-gated calcium (SA-Cat) channels that are known to 
5 play a role in bone formation. Recent studies indicate that a 
similar voltage-gated calcium channel is present in endot- 
helial cells. Stretch-activated cation channels are, as the 
name suggests, activated by mechanical stimuli, e.g., 
mechanical loading or osmotic change. SA-Cat channels are 
10 voltage-independent, gadolinium-inhibitable and cation 
non-selective. In the present patent application we identify 
the osteoblast voltage-gated calcium channel as a member of 
the calcium channel superfamily, namely a CaCh2 isoform. 
Osteoporosis is a debilitating disease characterized by the 
loss of normal bone density with the thinning of bone tissue 
and the growth of small holes in the bones. Osteoporosis 
frequently causes chronic pain, especially in the lower back, 
increased frequency of broken bones, loss of body height, 
and eventual loss of mobility and other body function. 
2o Osteoporosis has been classified into two categories. Pri- 
mary osteoporosis, which includes post-menopausal 
osteoporosis, and secondary osteoporosis, which includes 
immobilization or disuse osteoporosis, together afflict 
approximately 20 million Americans. 
Osteosclerosis is a lesser-known condition characterized 
by an abnormal increase in the density of bone mass. The 
condition occurs in various diseases and is often linked to 
poor circulation in the bone tissue, infection or tumor 
Hypertension is a common, generally asymptomatic dis- 
ease marked by high blood pressure persistently exceeding 
140190. Essential hypertension, also known as primary 
hypertension, has no single known cause, and is the most 
35 prevalent form of hypertension, having been diagnosed 
according to some estimates, in over 50 million Americans. 
Secondary hypertension is linked to disease of the kidneys, 
lungs, glands or vessels. For example, pulmonary hyperten- 
sion is a condition of unusually high pressure within the 
Antisense oligonucleotides are short synthetic nucleotide 
sequences formulated to be complementary to a portion of a 
specific gene or mRNA. They function by hybridizing to 
complementary sequences, resulting in selective arrest of 
45 expression of the complementary gene or mRNA. In 
particular, the cytoplasmic location of mRNA provides a 
readily accessible target for antisense oligonucleotides 
entering the cell. In addition to the use of antisense oligo- 
nucleotides as therapeutic agents due to their ability to block 
50 expression of a specific target protein, they also provide a 
useful tool for exploring regulation of the expression of a 
gene of interest in vitro and in tissue culture (see 
Rothenberg, M., et al., Nutl. Cancer Znst., 81:1539-1544, 
1989). 
The development of new therapeutic strategies against, 
and the creation of new analytical tools for, a better under- 
standing of diseases such as osteoporosis, osteosclerosis, 
and hypertension, are greatly desired. It is particularly 
desirable to provide such tools and therapies that are highly 
60 specific to a target gene and protein, which at the same time, 
because of their specificity, do not substantially affect other 
proteins or body functions. The provision of antisense 
oligonucleotides for use in designing therapies and diagnos- 
tic tools for diseases and physiological responses related to 
65 voltage-gated calcium channel mediated physiological 
activities satisfies a long-sought need for such therapies and 
tools. 
25 
3o formation. 
4o blood vessels of the lungs. 
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SUMMARY OF THE INVENTION 
Among the objects of the invention, therefore, may be 
noted the provision of antisense oligonucleotides and phar- 
maceutical compositions that are capable of inhibiting the 
function of the voltage-gated calcium gene or mRNA and 
the provision of such oligonucleotides and compositions that 
serve as useful tools for exploring the regulation of gene 
expression in vitro and in tissue culture for the voltage-gated 
calcium. Also provided are a method for selectively block- 
ing transcription or translation of the voltage-gated calcium 
channel gene and mRNA, for halting disease processes 
associated with the expression of that gene, and therapeutic 
procedures for the treatment of osteosclerosis and hyperten- 
sion. 
Briefly, therefore, the present invention is directed to an 
antisense oligonucleotide of 10 to 35 nucleotides in length 
that can hybridize with a region of the a1 subunit of the 
voltage-gated calcium channel gene DNA or mRNA. 
In a further embodiment, the invention is directed to a 
pharmaceutical composition comprising at least one anti- 
sense oligonucleotide of 10 to 35 nucleotides in length that 
is capable of hybridizing with a region of the a1 subunit of 
the voltage-gated calcium channel gene DNA or mRNA and 
a pharmaceutically acceptable carrier. 
In another aspect of the present invention, a method of 
inhibiting expression of the voltage-gated calcium channel 
gene is provided. The method comprises the steps of obtain- 
ing an antisense oligonucleotide of 10 to 35 nucleotides in 
length that can hybridize with a region of the a1 subunit of 
the voltage-gated calcium channel gene DNA or mRNA, 
combining the antisense oligonucleotide with a pharmaceu- 
tically acceptable carrier to create a pharmaceutically active 
mixture, and contacting the pharmaceutically active mixture 
with the a1 subunit of the voltage-gated calcium channel 
gene DNA or mRNA, thereby inhibiting expression of the 
voltage-gated calcium channel protein. 
In yet another embodiment of the instant invention, a 
method of treating hypertension using the antisense oligo- 
nucleotides to the voltage-gated calcium channel gene is 
provided. The method includes the steps of obtaining a 
hypertensive-reductive amount of an antisense oligonucle- 
otide 10 to 35 nucleotides in length that can hybridize with 
a region of the a1 subunit of the SA-Cat channel gene DNA 
or mRNA, combining the hypertensive-reductive amount of 
the antisense oligonucleotide with a pharmaceutically 
acceptable carrier to create a pharmaceutically active 
mixture, and contacting the pharmaceutically active mixture 
with the a1 subunit of the voltage-gated calcium channel 
gene DNA or mRNA of endothelial cells lining the blood 
vessels, inhibiting expression of the voltage-gated calcium 
channel protein and thereby causing a reduction in blood 
pressure. 
In a further embodiment of the instant invention, a method 
of treating osteoscierosis using the antisense oligonucle- 
otides to the voltage-gated calcium channel gene is pro- 
vided. The method includes the steps of obtaining an 
osteosclerotic-reductive amount of an antisense oligonucle- 
otide 10 to 35 nucleotides in length that can hybridize with 
a region of the a1 subunit of the voltage-gated calcium 
channel gene DNA or mRNA, combining the osteosclerotic- 
reductive amount of the antisense oligonucleotide with a 
pharmaceutically acceptable carrier to create a pharmaceu- 
tically active mixture, and contacting the pharmaceutically 
active mixture with the a1 subunit of the voltage-gated 
calcium channel gene DNA or mRNA of osteoblasts in a 
target tissue, inhibiting expression of the voltage-gated 
4 
calcium channel protein and thereby causing a reduction in 
bone density in the target tissue. 
Other objects and features will be in part apparent and in 
part pointed out hereinafter. 
BRIEF DESCRIPTION OF THE DRAWINGS 
SEQ ID NO.l depicts the cDNAencoding for a region of 
the a1 subunit of the voltage-gated calcium channel protein. 
FIG. 1 is a schematic depiction of a model of an L-type 
calcium channel a1 subunit such as the voltage-gated cal- 
cium channel of the invention. The channel is composed of 
four homologous domains (I-IV) that are modeled to con- 
tain six transmembrane regions ( S l S 6 ) ,  and a segment (H5 
or SS1-SS2) between the S5 and S6 domains, which is 
thought to loop into the membrane and line the external 
entrance to the pore of the channel. The IVS3 region is 
shaded to indicate that alternative splicing can generate two 
variants of this region. The hatched line just downstream of 
the S3 region indicates the site where a segment is omitted 
in the bone transcripts as a result of alternative splicing. 
FIG. 2 depicts a comparison of the deduced amino acid 
sequences of the UMR-106 clone with its corresponding 
CaCh isoform in the region where alternative splicing gen- 
erates a deletion (ROB2 to the rat brain CaCh2 transcript 
(RatBr2). 
FIG3 is an autoradiogram of a Northern blot of RNA 
hybridized to UMR-106, calcium channel riboprobes. A 
riboprobe corresponding to clones ROB2 was hybridized to 
poly (A+) RNA (10 pugilane) isolated from UMR-106 cells. 
The actin riboprobe was hybridized to one-tenth as much 
3o RNA(1 pgilane). Autoradiography was for 67 hours (ROBS) 
or 6 hours (actin). The actin riboprobe, which was used as 
a control, hybridized to a single mRNA band of approxi- 
mately 2.0 kB. An RNA ladder (GibcoBRL) was used for 
size markers (in Kilobases). FIGS. 4(a) and 4(b) are graphic 
representations of the effect of a preferred antisense 24mer 
35 oligonucleotide from the a1 subunit of the voltage-gated 
calcium channel gene (SEQ ID NO.:2) on the response of 
membrane potential and whole cell conductance to hypo- 
tonic stretch. FIG. 4(a) depicts the UMR-106 cell membrane 
potential and whole cell conductance response to hypotonic 
40 stretch and reversal to isotonic media. The cells had been 
exposed to chronic cyclic strain for nineteen hours. FIG. 
4(b), depicts the same information as in FIG. 6(a), except 
that the cells had been loaded with the antisense oligonucle- 
otide (SEQ ID NO:2). 
FIGS. 5(A) and 5(B) are graphic representations of the 
effect of a preferred antisense 20mer oligonucleotide from 
the a1 subunit of the voltage-gated calcium channel gene 
(SEQ ID NO.:3) on the response to hypotonic stretch. FIG. 
7(a)  depicts the UMR-106 cells exposed to anti-streptolysin 
0 but without exposure to the antisense oligonucleotide, 
exposed to 18 hrs of chronic cyclic strain prior to hypotonic 
stretch. FIG. 5(B) depicts the same procedure, but with 
exposure of the cells to the 20mer antisense oligonucleotide 
during the permeabilization. 
FIG. 6 is a graphic representation of the effect of a sense 
24mer oligonucleotide corresponding to the same sequence 
as in FIG. 4(b) on the response of UMR-106 cells to 
hypotonic stretch (as a control). Cells were loaded with the 
sense oligonucleotide in parallel with the antisense oligo- 
nucleotide used in FIG. 4(b) eighteen hours prior to study 
6o during which time the cells were exposed to chronic cyclic 
strain as described in Example 2 (Methods). 
5 
10 
20 
2s 
45 
55 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
The term “oligonucleotide” as used herein means a mol- 
ecule comprised of two or more deoxyribonucleotides, 
ribonucleotides, analogs or derivatives thereof. 
65 
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“Oligonucleotide analog” or “oligonucleotide derivative,” 
as those terms are used in conjunction with this invention, 
refer to moieties that function similarly to deoxyribonucle- 
otides or ribonucleotides, but that have non-naturally occur- 
ring portions. Thus, oligonucleotide analogs may have 
altered sugar moieties or inter-sugar linkages. Exemplary 
among these are the phosphorothioate and other sulfur- 
containing species that are known to be useful in this art. 
They may also contain altered base units or other modifi- 
cations consistent with the function of oligonucleotides in 
conjunction with this invention. 
In accordance with the invention, it has been demon- 
strated that an isoform of the voltage-gated CaCh2b channel, 
an voltage-gated calcium channel protein, is activated by 
chronic mechanical loading and parathyroid hormone 
(PTH), two factors known to have anabolic or positive 
effects on bone formation in osteoblasts. Based on the ability 
of antisense oligonucleotides to the voltage-gated calcium 
channel protein to block the increase in whole cell conduc- 
tance shown to be triggered by the application of chronic, 
intermittent mechanical strain to osteoblasts, it has further 
been demonstrated in accordance with this invention that the 
voltage-gated calcium channel is the signaling mechanism at 
the molecular level for increasing bone formation in 
response to mechanical strain. 
As a consequence of these and other discoveries described 
herein, it is believed that application of an antisense strategy 
against expression of the voltage-gated calcium channel 
protein in osteoblasts will directly inhibit the abnormally- 
high bone density formation reflected in the condition 
known as osteosclerosis. Moreover, these discoveries pro- 
vide an important analytical tool for and a critical link in the 
development of methods for the pharmacologic modulation 
of this channel for clinical treatment of osteoporosis. Thus, 
it is believed that stimulation of the voltage-gated calcium 
channel, which serves as a signal transducer for mechanical 
strain, for example by application of an agonist active in 
stimulating the expression of the voltage-gated calcium 
channel protein, will promote the beneficial properties of 
exercise on bone without the physical exertion that is 
difficult or impossible for elderly or paralyzed patients or for 
those unable to enjoy the beneficial effects of strain imposed 
by Earth’s gravity due to extended space flight. 
Recent laboratory research also has demonstrated that 
shear stress, or the mechanical stimulation of the endothelial 
cells lining the blood vessels by the flow of blood, plays a 
role in the control of blood pressure. Furthermore, stretching 
endothelial cells in vitro increases endothelin production and 
cell proliferation through an increase in intracellular cal- 
cium. The increase in intracellular calcium is blocked by 
gadolinium, a SA-Cat channel inhibitor, suggesting that the 
SA-Cat channel also transduces the mechanical strain 
induced by shear stress into cellular biochemical message 
either to relax or contract the blood vessel. Therefore, 
modulation of this channel by application of an antisense 
strategy is also believed to provide the clinician with a 
means of controlling blood pressure. 
These discoveries and their application will be explained 
in greater detail below. 
Mechanical strain increases bone formation and remod- 
eling activity resulting in increased bone mass. Osteoblasts 
have stretch activated cation (SA-Cat) channels that are 
6 
modulated by parathyroid hormone. Chronic, intermittent 
strain increases the sensitivity of SA-Cat channels to stretch 
increasing the number of channels open at any given time 
period and increasing single channel conductance. As a 
s result, an increase in whole cell conductance is demon- 
strable. Furthermore, spontaneous activity of these channels 
is observed in chronically strained osteoblasts. These prop- 
erties have not been previously demonstrated for SA-Cat 
channels, and they demonstrate that during mechanical 
i o  loading of the osteoblast, SA-Cat channels are an integral 
component of the electrical environment and ion flux of the 
cell. 
Chronic, intermittent strain applied to osteoblast-like cells 
not only affects ion conductance through SA-Cat channels, 
it also increases gene transcription for the bone matrix 
proteins. Application of cyclic strain for 24-72 hrs to 
osteoblast-like cell cultures increases type-1 procollagen 
message and type-1 collagen secretion. Chronic, intermittent 
strain also upregulates osteopontin message levels and 
2o osteocalcin secretion independent of, but additive to, 1,25 
(OH), Vitamin D, stimulation. 
Calcium channel transcripts in UMR-106 cells were iden- 
tified using the homology-based reverse transcriptase poly- 
merase chain reaction. Primers were designed from regions 
that are highly conserved between L-type calcium channels 
to amplify essentially the entire fourth domain. An 850 base 
pair clone was isolated, which, upon sequencing, was found 
to be a CaCh2b variant. In addition, clones corresponding to 
CaChlb and CaCh3b variants were isolated. The nucleotide 
sequence of the cDNA for the CaCh2b clone is set forth in 
Table 1. This Table depicts the nucleotide sequence of a 
partial cDNA clone encoding the fourth domain of the a1 
subunit of L-type calcium channel isoforms CaChl (ROBl), 
CaCh2 (ROB2), and CaCh3 (ROB3) isolated from rat 
osteosarcoma UMR-106 cells. The putative transmembrane 
domains S 1 S 6  are indicated by heavy lines under the 
sequence. The symbol A indicates the site of omission of a 
segment by alternative splicing in the CaCh2b isoform. 
Employing an antisense strategy, in accordance with the 
invention we have demonstrated the ability to inhibit the 
response of osteoblast-like cells to chronic, cyclic strain. 
Thus, we have shown that antisense oligonucleotides to the 
CaCh2 transcript eliminates the biophysical properties of the 
4s voltage-gated calcium channel in the cells. Voltage-gated 
calcium channel activity is eliminated by application of the 
antisense oligonucleotide. 
Antisense therapy is the administration of exogenous 
oligonucleotides that bind to a target polynucleotide located 
SO within the cells. The term “antisense” refers to the fact that 
such oligonucleotides are complementary to their intracel- 
lular targets, e.g., the voltage-gated calcium channel gene or 
m R N A .  S e e  f o r  e x a m p l e ,  J a c k  C o h e n ,  
Oligodeoxynucleotides, Antisense Inhibitors of Gene 
ss Expression, CRC Press, 1989; and Synthesis 1:l-5 (1988). 
The voltage-gated calcium channel antisense oligonucle- 
otides of the present invention may be RNA or DNA that is 
complementary to and stably hybridizes with the DNAof, or 
the mRNA derived from, the voltage-gated calcium gene. 
60 Preferably, the antisense oligonucleotides are designed to 
maximize their specificity for the CaCh2 isoform relative to 
the CaChl and CaCh3 isoforms. Such specificity may be 
achieved by selecting sequences that 
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are not highly conserved between the isoforms. In general, Although use of the antisense strategy is not directly 
only one or two (e.g., 1 in 20) base pair mismatches in a applicable to therapies for treating osteoporosis, antisense 
relatively short oligonucleotide are sufficient to exclude oligonucleotides of the present invention represent impor- 
hybridization to non-targeted isoforms. The voltage-gated tant analytical tools for studying mechanisms to trigger, 
calcium channel antisense oligonucleotides of the present s rather than inhibit, the expression of voltage-gated calcium 
i n v e n t i o n  a l s o  i n c l u d e  d e r i v a t i v e s  s u c h  a s  channels in osteoblasts to signal enhanced bone matrix 
S-oligonucleotides (phosphorothioate derivatives or formation. Such further investigation using the antisense 
S-oligos) which exhibit voltage-gated calcium channel oligonucleotides as an analytical tool may provide the basis 
inhibitory action. for developing agonists for the voltage-gated calcium chan- 
S-oligos (nucleoside phosphorothioates) are isoelectronic i o  ne1 signaling mechanism that can upregulate the level of 
analogs of an oligonucleotide (0-oligos) in which a non- bone matrix formation to counteract the loss of bone density 
bridging oxygen atom of the phosphate group is replaced by caused by osteoporosis. 
a sulfur atom. The S-oligos of the present invention may be The present invention is additionally useful in diagnostics 
prepared by treatment of the corresponding 0-oligos with and in research in respects other than those specifically 
3H-1,2-benzodithiol-3-one-l,l-dioxide, which is a sulfur is referenced above. It is believed that the voltage-gated cal- 
transfer reagent. See Iyer, R. P. et al., J.  Ovg. Chem. 
55:46934698 (1990), the disclosures of which are fully 
incorporated by reference herein. The above substitutions 
are known in the art to function to enhance the ability of the 
compositions to penetrate into the region of cells where the 
RNA whose activity is to be modulated is located. Others, 
such as  a lkyl  phosphorothioate  bonds,  N-alkyl 
p h o s p h o r a m i d a t e s ,  p h o s p h o r o d i t h i o a t e s ,  a l k y l  
phosphonates, and short chain alkyl or cycloalkyl structures 
mav also be useful. Persons with ordinarv skill in the art will 
cium channels play roles in tissues not yet fully explored. 
Since the oligonucleotides of this invention hybridize to 
voltage-gated calcium channels, sandwich and other assays 
can easily be constructed to exploit this fact. Provision of 
20 means for detecting hybridization of oligonucleotides with 
voltage-gated calcium channels in tissue samples suspected 
of containing this channel may be accomplished by such 
means as enzyme conjugation, radiolabelling or other suit- 
able detection systems. 
Also included in the aresent invention are aharmaceutical zs 
be able to select other linkages for use in the practice of the compositions comprising an effective amount of at least one 
invention. of the voltage-gated calcium channel antisense oligonucle- 
Oligonucleotide analogs may also include species that otides of the invention in combination with a pharmaceuti- 
include at least some modified base forms. Thus, purines and cally acceptable carrier. The voltage-gated calcium channel 
pyrimidines other than those normally found in nature may 30 antisense oligonucleotides are preferably coadministered 
be so employed. Similarly, modifications on the furanose with an agent which enhances the uptake of the antisense 
portions of the nucleotide subunits may also occur as long as molecule by the cells. For example, the voltage-gated cal- 
the essential tenets of this invention are adhered to. All such cium channel antisense oligonucleotides may be combined 
analogs are comprehended by this invention so long as they with a lipophilic cationic compound, which may be in the 
function effectively to hybridize with DNA of or with 3s form of liposomes. The use of liposomes to introduce 
mRNAderived from the voltage-gated calcium channel gene nucleotides into cells is taught, for example, in U.S. Pat. 
to inhibit the function of that DNA or mRNA. Nos. 4,397,355 and 4,394,448, incorporated herein by ref- 
The antisense oligonucleotides of this invention prefer- erence. Alternatively, the voltage-gated calcium channel 
ably comprise about 10 to about 35 bases, preferably from antisense oligonucleotides may be combined with a lipo- 
about 15 to 30, and most preferably about 18 to about 26. 40 philic carrier such as any one of a number of sterols 
Two preferred embodiments of the antisense oligonucleotide including cholesterol, cholate and deoxycholic acid. A pre- 
sequences of the present invention are a 24 mer antisense ferred sterol is cholesterol. 
oligonucleotide having SEQ. ID NO: 2 and a 20 mer In addition, the voltage-gated calcium channel antisense 
antisense oligonucleotide having SEQ. ID NO: 3. These oligonucleotide may be conjugated to a peptide that is 
antisense oligonucleotides act just on the 5'-side of the S6 4s ingested by cells. Examples of useful peptides include 
region of the IV domain of the voltage-gated calcium peptide hormones or antibodies. By choosing a peptide that 
channel a1 subunit. is selectively taken up by the neoplastic cells, specific 
The oligonucleotides of this invention are designed to delivery of the antisense agent may be effected. The voltage- 
hybridize with DNA or mRNA of the voltage-gated calcium gated calcium channel antisense oligonucleotide may be 
channel. Such hybridization, when accomplished, interferes SO covalently bound via the 5'H group by formation of an 
with the normal function of these DNNmRNAcomponents. activated aminoalkyl derivative. The peptide of choice may 
Such inhibited functions may include transcription of the then be covalently attached to the activated voltage-gated 
DNA to mRNA, translocation of the RNA to the site of calcium channel antisense oligonucleotide via an amino and 
protein translation, and actual translation of protein from the sulfydryl reactive hetero bifunctional reagent. The latter is 
mRNA. The overall effect of the interference caused by the ss bound to a cysteine residue present in the peptide. Upon 
antisense oligonucleotides of the invention is to cause inhi- exposure of cells to the SA-Cat channel antisense oligo- 
bition of the expression of the voltage-gated calcium chan- nucleotide bound to the peptide, the peptidyl antisense agent 
ne1 protein. Since it has been established that the voltage- is endocytosed and the voltage-gated calcium channel anti- 
gated calcium channel protein is a component of the sense oligonucleotide binds to the target voltage-gated cal- 
signaling mechanism for stretch-induced increased bone 60 cium channel mRNA to inhibit translation. 
formation in osteoblasts, such inhibition works directly to The voltage-gated calcium channel antisense oligonucle- 
reduce the abnormally-high bone density exhibited in otides and the pharmaceutical compositions of the present 
patients suffering from osteosclerosis. Similarly, it is invention may be administered by any means that achieve 
believed that inhibition of voltage-gated calcium channel their intended purpose. For example, administration may be 
expression in endothelial tissue by antisense oligonucle- 65 by parenteral, subcutaneous, intravenous, intramuscular, 
otides will inhibit the enhanced cell proliferation and con- intraperitoneal, or transdermal routes. The dosage adminis- 
comitant cellular changes which cause hypertension. tered will be dependent upon the age, health, and weight of 
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the recipient, type of concurrent treatment, if any, frequency Cell Culture-UMR-106 cells were cultured in D-MEM/ 
of treatment, and the nature of the effect desired. For Ham's F-12 medium containing 5% fetal bovine serum. 
treatment of osteoscierosis, an osteosclerotic-reductive Cells were used between passages 3 and 17. 
amount is to be administered. For treatment of hypertension, Purification of RNA-Poly (A+) RNA was isolated from 
a hypertensive-reductive amount is to be applied. 5 cultured cells as described in Bradley, J. E., et al., Biotech- 
Compositions within the scope of this invention include niques 6, 114-116 (1988) using the FastTrack mRNA Iso- 
all compositions wherein the voltage-gated calcium channel lation Kit. Briefly, UMR-106 cells were grown to confluence 
antisense o~igonuc~eotide is contained in an amount that is in P-100 culture dishes, washed in phosphate-buffered saline 
effective to achieve inhibition of expression of the voltage- (137 mM NaC1, 2.6 mM KC1, lo mM N a 2 H P 0 4 2  1.8 mM 
gated calcium channel protein sufficient to, when applied to IO K H 2 p 0 4 2  PH 7.4) and harvested were 
osteoblasts, ameliorate osteosclerosis, and when applied to pelleted by centrifugation and homogenized with a Pob'tron 
endothelial tissue, in the presence of 2% SDS. After incubation with proteinase 
in blood pressure, either in localized tissue or system-wide. K, the lysate was batch adsorbed to Olig0 (dT) cellulose 
Although individual needs vary, determination of optimal and Poly (A+) RNA was in buffer. APProxi- 
ranges of effective amounts of each component is within the IS mately 2o iug Of poly (A+) RNA was from lX1O8 
skill of the art. cells. 
In addition to administering the voltage-gated calcium CDNA synthesis and PCR-polY (A+) RNA was reverse 
channel antisense oligonucleotides as a raw chemical in transcribed and CDNA was amplified using the GeneAmP 
solution, the voltage-gated calcium channel antisense oligo- RNA PCR kit as f ~ ~ ~ ~ ~ ~ .  Poly (A+) RNA, 250 ng, was 
nucleotides may be administered as part of a pharmaceuti- 20 incubated in a 20 iul reaction volume containing 2.5 uiiu1 
tally active mixture or preparation containing suitable phar- Moloney murine leukemia viral reverse transcriptase, 2.5 
maceutically acceptable carriers comprising excipients and PM random hexamers, 1.0 mM dNTPs and 1 Uh1 RNase 
auxiliaries that facilitate processing of the voltage-gated inhibitor in 50 mM KC1, 5 mM MgCL, and 10 mM 
calcium channel antisense oligonucleotide into preparations Tris-HC1, PH 8.3, for 10 min at room temperature followed 
that can be used pharmaceutically. 2~ by 15 min at 42" C. and 5 min at 99" C. Subsequently, the 
Suitable formulations for parenteral administration samples containing first strand cDNA were brought up to a 
include aqueous solutions of the voltage-gated calcium 100 iu1 reaction volume containing 10 mM Tris-HCl, pH 8.3, 
channel antisense oligonucleotides in water-soluble form, 50 mM KCL 2.0 mM MgCL 200 
for example, water-soluble salts. In addition, suspensions of of each Primer, and 2.5 units of AmPliTaq DNAPolYmerase 
the active compounds as appropriate oily injection suspen- 30 and overlaid with 75 ~1 of mineral oil. PCR was performed 
sions may be administered. Suitable lipophilic solvents or on an automated thermal cycler (Model 4802 Perkin-Elmer 
vehicles include fatty oils, for example, sesame oil, or Cetus) that was Programmed to repeat the following cycle 
synthetic fatty acid esters, for example, sodium carboxym- 30 times: 60 S at 94" c.2 60 S at 60" c .  and then 120+2 
ethyl cellulose, sorbitol, and/or dextran. Optionally, the s/cYcle at 72" c .  
suspension may also contain stabilizers. PCR primers-Oligodeoxynucleotide PCR primers were 
The antisense oligonucleotides of the present invention designed from regions that are highly conserved between 
may be prepared according to any of the methods that are L-type calcium channels using the following published 
well known to those of ordinary skill in the art. Preferably, sequences: CaCh 1 (rabbit skeletal muscle isoform) Tanabe, 
the antisense oligonucleotides are prepared by solid phase T. et al. (1987) Nature 328, 313-318, CaCh2 (rat cardiac 
synthesis. See, Goodchild J. Bioconjugate Chemistry, 40 muscle isoform) Snutch, T. P. et al. (1991) Neuron 7, 45-57 
1:1650167 (1990), for a review of the chemical synthesis of and CaCh3 (rat neuroendocrine isoform) Hui, A. et. al. 
oligonucleotides. Alternatively, the antisense oligonucle- (1991) Neuron 7, 35-44. Two pairs of primers were used. 
otides can be obtained from a number of companies which One set spanned the entire calcium channel domain I V  
specialize in the custom synthesis of oligonucleotides. u p s t r e a m  p r i m e r - 1  ( U P - 1 ) :  5 ' - g c c  
45 neatccatcgtcaccttccaggagca-3'(SEQ ID NO: 13); and down- 
stream primer (DP-1): 5'-atggaattcgccacraagaggttgatgat-3' 
EXAMPLE 1 (r=a or g)(SEQ ID NO: 14). A second set spanned domain 
Materials-UMR-106 cells were obtained from American IVS5 through IVS6: upstream primer-2 (UP-2 ): 5'-gtg 
Type Culture Collection (Rockville, Md.). Cell culture ggaattcatcaagtccttccaggccct-3'(SEQ ID NO: 15) and down- 
media and serum were purchased from Sigma. Sources for so s t r e a m  5 ' - c a g g 
other materials were as follows: Fast Track mRNA Isolation neatccaagttgtccatgataacag~-3'(SEQ ID NO: 16). An addi- 
Kit (hvitrogen Corp., San Diego, Calif.), GeneAmp RNA t i o n a l  d o w n s t r e a m  p r i m e r ,  ( D S - 3 ) :  5 ' - c c c  
PCR kit (Perkin Elmer Cetus, Nonvalk, Conn.), pBluescript gatkakmgtgttgagcatgatgag-3' (k=t or g, m=a or c)(SEQ ID 
KS- vector and XL-1 Blue bacteria (Stratagene, La Jolla, NO: 17), was designed from sequence in the IVSl segment 
Calif,), Nuseive, Seakem and Seaplaque agarose (FMC 5s of the UMR-106 ROB1 and ROB3 clones to be used with 
Bioproducts, Rockland, Me.), Sequenase I1 kit (United the UP-1 primer to amplify only the 5' end of those clones. 
States Biochemical Corp., Cleveland, Ohio), DNA ligase Bam H1 or Eco R1 restriction sites (underlined) were 
(Boehringer Mannheim, Indianapolis, Ind.), acrylamide included near the 5' ends of the primers to facilitate direc- 
(Gel-Mix 8, GibcoiRRT,, Gaithersburg, Md.), DNA purifi- tional subcloning. 
cation kit PZ523 Kit (5 Prime+3 Prime, Inc., Boulder, 60 Cloning PCR products-The products of the PCR reac- 
Colo.), Genescreen Plus nylon membrane (Du Pont NEN tion were directionally cloned into the pBluescript KS- 
Research Products, Boston, Mass.). Labeled probes were vector. Initially, one half of each PCR reaction was analyzed 
prepared using the Riboprobe Gemini System (Promega by electrophoresis on 1% Nuseive/l% Seakem agarose gels. 
Corp., Madison, Wis.). [a3'P]UTP was purchased from For subcloning, the remaining reaction product was purified 
Amersham. Oligonucleotides were synthesized commer- 65 by phenol/chloroform/Isoamyl alcohol (25:24: 1) extraction 
cially by Macromolecular Resources (Fort Collins, Colo.). and ethanol precipitation, digested with Eco R1 and Bam 
Restriction enzymes were purchased from Gibco/BRL. H1, and isolated as a band from a low melting temperature 
a measurably significant reduction 
of each dNTP, 0.2 
35 
The following examples illustrate the invention. 
p r i m  e r - 2 ( D s - 2 )  : 
5,824,550 
15 
1% Seaplaque agarose gel. The vector was also digested 
with Eco R1 and Bam H1 and isolated on a low melt agarose 
gel. The ligation reaction was carried out in a 50 pl volume 
containing 5 U T4 DNA ligase in 66 mM Tris-HC1, 5 mM 
MgCl,, 1 mM dithioerytritol, 1 mM ATP, pH 7.5. Agarose 
gel slices containing the PCR product or vector were melted 
at 70" C. for 10 rnin before the addition of 2-4 pl  to the 
reaction. The ligation reaction was incubated at 15" C. for 16 
h. One tenth of each ligation reaction was used to transform 
XL-1 Blue bacteria. Competent bacteria were prepared by 
the calcium chloride method and transformed according to a 
standard protocol (Sambrook, J., et al., Molecular Cloning: 
A Laboratovy Manual, 2nd Ed., 1989). Transformants were 
plated onto LB (10 giL tryptone, 5 giL yeast extract, 10 giL 
NaC1) agar plates containing 50 pgiml ampicillin and 12.5 
pgiml tetracycline that had been coated with 10 pl of 2% 
5-bromo-4-chloro-3-indoyl-~-D-galactopyranoside and 40 
pl of 100 mM isopropyl-0-D-thiogalactopyranoside. Indi- 
vidual white colonies were picked and grown overnight in 5 
ml of LB medium containing 50 pgiml ampicillin at 37" C. 
Plasmid DNAwas prepared from 3.0 ml of overnight culture 
by alkaline lysis. The presence of an appropriately sized 
insert was confirmed by Eco R1 and Bam H1 restriction 
digestion of the plasmid DNA. 
Sequencing of Double-Stranded DNA Templates- 
Plasmid DNA, 5 pg, was denatured in 200 mM NaOH, 0.2 
mM EDTAfor 30 rnin at 37" C., neutralized and precipitated 
in ethanol. Sequencing was by the dideoxynucleotide chain 
termination method using the Sequenase I1 kit. The products 
were separated by electrophoresis on 8.0% acrylamide gels. 
Some sequencing was also performed on an automated 
instrument (Applied Biosystems, Foster City, Calif.) using 
plasmid DNA purified with the PZ523 Kit. The final 
sequences were determined from both strands of the cDNA. 
Sequence analysis was performed using on-line software 
from the Genetics Computer Group, Inc. (Madison, Wis.). 
Northern Blot Analysis-Poly (A+) RNA was electro- 
phoresed on a 0.75% agaroseiformaldehyde denaturing gel 
and eletrophoretically transferred to Genescreen Plus nylon 
membrane. The membranes were UV-crosslinked and baked 
for 2 h at 80" C. under vacuum. Prehybridization was carried 
out in 0.25 m NaPO,, pH 7.2, 0.25 M NaC1, 1 mM EDTA, 
50% formamide, 6% SDS at 55" C. for 1 hr. [32P]-labeled 
RNA probes were synthesized form linearized cDNA tem- 
plates using the Riboprobe Gemini System. Hybridization 
with riboprobes, 2x106 cpmiml, was under the same condi- 
tions as the prehybridization for 20 h. The membranes were 
washed twice in 0.3M NaC1, 0.03M Na,Citrate, pH 7.0 (2x 
SSC) for 5 rnin at room temperature; twice in 0.25M NaPO,, 
pH 7.2, 2% SDS, 1 mM EDTA for 30 rnin at 65" C.; and 
twice in 0.04 M NaPO,, pH 7.2, 1% SDS, 1 mM EDTA for 
30 rnin at 65" C. To decrease the background, the mem- 
branes were subsequently rinsed three times in 2x SSC for 
5 min at room temperature, incubated in 2x SSC containing 
1 pgiml RNase A for 15 rnin at room temperature, and 
washed twice in 0.04M NaPO,, pH 7.2, 1% SDS, 1 mM 
EDTAfor 30 rnin at 65" C. Autoradiography was carried out 
at -70" C. with an intensifying screen. Hybridization with a 
riboprobe for human 0-actin was used as a positive control. 
RESULTS 
Homology-based reverse transcriptase-PCR was used to 
identify transcripts for L-type calcium channels that are 
present in UMR-106 cells. Primers were designed from 
regions that are highly conserved between L-type calcium 
channels to amplify essentially the entire fourth domain 
(FIG. 1). Three types of cDNA clones were isolated, corre- 
16 
sponding to all three of the known L-type calcium channel 
genes. The CaCh2 isoform (Table 1, ROB2), 850 base pairs, 
is identical to the rat brain rbC-I transcript (22), except for 
a 33 base pair (11 amino acids) deletion (FIG. 2) in the 
s S3-S4 linker. This isoform has subsequently been deter- 
mined (see below) to be a close isoform of the voltage-gated 
calcium channel gene. 
Alternative splicing in the fourth domain of L-type cal- 
cium channels can potentially give rise to four variants of 
10 CaCh2 (CaCh2a, b, c, d) transcripts (Perez-Reyes, E., et al., 
J .  Biol. Chem. 265, 20430-20436 (1990)). This occurs 
through the use of an alternate splice acceptor site or an exon 
skipping event in the extracellular IVS3-S4 linker that 
produces two sizes of transcripts. In addition, mutually 
15 exclusive splicing of alternate exons (approximately 50% 
homologous) encoding the transmembrane IVS3 domain 
occurs in CaCh2 transcripts (Perez-Reyes, Supra). 
According to the Perez-Reyes nomenclature, each of the 
three L-type CaCh transcripts isolated from UMR-106 cells 
2o are of the b type since they contain a specific IVS3 variant 
and they lack a portion of the IVS3-S4 linker region. 
Northern analysis was used to detect expression of mRNA 
transcripts corresponding to the UMR-106 calcium channel 
clones (FIG. 3). (Three sizes of mRNAs of approximately 
25 11.7, 8.6, and 4.8 kB were detected.) The ROB2 clone 
hybridized predominately to the 8.6 kB MRNA, which is the 
expected size for a CaCh2 isoform transcript. However a 
larger 12-15 kB transcript detected in other tissues (22,26, 
27), including cardiac muscle, aorta, and brain, was not seen. 
30 Very high stringency was used during Northern analysis to 
maximize the specificity of hybridization. Nevertheless, it is 
possible that the high degree of sequence identity 
(approximately 76%) between each of the three CaCh iso- 
forms in the region cloned may be responsible for some 
35 cross-hybridization as a result of the relatively high abun- 
dance of those transcripts. 
METHODS 
Cell culture: UMR-106.01 cells (passages 12-18) were 
grown in Minimal Essential Medium with Eagles 
modification, non-essential amino acids and Earle's salts 
(Sigma, St. Louis, Mo.) supplemented with 10% fetal bovine 
serum (Gibco, Grand Island, N.Y.). Cells were plated onto 
45 flexible, type I collagen-coated, silicone-bottomed 6 well 
culture plates (Flexcell, Inc., McKeesport, Pa.), fed twice 
weekly and maintained in a humidified atmosphere of 95% 
air/5% CO, at 37" C. When the cells were approx. 75% 
confluent, they were transfected with either the sense or 
SO antisense oligodeoxynucleotides (oligonucleotide) as 
described below. Culture plates were placed on the Flexer- 
cell apparatus which uses vacuum to stretch the silicone 
bottoms and cyclic stretch was applied for 12-30 hrs at 3 
cyclesimin. A maximal strain of 12% displacement was 
ss applied at the edge of the culture plate falling to 0% 
displacement at the center. 
Transfection of oligonucleotide's. Two antisense oligo- 
nucleotides (24-mer and 20-mer)(respectively, SEQ ID NO: 
2 and NO: 3) and a sense (24-mer) oligonucleotide were 
60 developed from the sequence of a cDNA clone of the a1 
subunit of an L-type calcium channel (CaCh2) isolated from 
UMR-106 by reverse transcriptase-polymerase chain reac- 
tion (SEQ ID N0:l) .  The antisense oligonucleotides were 
commercially synthesized by Macromolecular Resources 
65 (Fort Collins, Colo.). The antisense oligonucleotides were 
introduced into the UMR cells using streptolysin 0 (Sigma, 
St. Louis, Mo.) permeabilization. After the UMR cells had 
EXAMPLE 2 
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been plated onto the flexible, silicone-bottomed culture 
plates and grown to 75% confluency, the medium was 
removed and the cells were washed with a permeabilization 
buffer consisting of (in mM): 137 NaC1, 5.6 glucose, 2.7 
KC1, 2.7 EGTA, 1 Na-ATP, 100 PIPES and 0.1% bovine s 
serum albumin, pH 7.4. The permeabilization buffer con- 
taining 0.5 Uiml strptolysin 0 and 100pM of the appropriate 
oligonucleotide was then placed on the cells for 5 min at 
room temperature. This solution was then removed and the 
normal medium with 10% fetal bovine serum was added to 
the cells. For control experiments, UMR cells were perme- 
abilized with the same concentration of streptolysin 0 with 
no oligonucleotide present. 
Patch Clamp Studies. Following application of chronic, 
intermittent strain, the silicone bottom of the cluster was 
removed and transferred to a recording chamber (1 ml total 
volume (Biophysica Technologies, Baltimore, Md.) which 
was modified to permit rapid exchange of the bathing 
solution with minimal perturbation to the cells. Cells were 
bathed in a mammalian Na+ Ringer’s solution consisting of 
(in mM): 136 NaC1; 5.5 KC1; 1 MgC1,; 1 CaC1,; and 20 
N-[2-hydroxyethyl]piperazine-N’-[2-ethane sulfonic acid] 
(HEPES) buffer; titrated to pH 7.3 with NaOH. The strain 
pattern associated with the Flexcell apparatus is non- 
uniform (1). The profiles of strain range from 120,000pE at 
the edge of the well (12% maximal displacement) to 0 pE at 
the center. The cells used in this study were subjected to 
similar magnitudes of strain since patches were always 
performed in an area lOmm from the edge of the well. Strain 
applied to this area estimated at 10,000 to 20,000 pE using 
the strain curve described by Banes, et al. Comparisons were 
made between chronically stretched control and 
oligonucleotide-treated cells from the same passage number 
and at the same level of confluency. To impose membrane 
strain on the UMR cells during the patch clamp studies, 10 
ml 65 mM NaCl (182 mOsm) hypotonic Ringer’s solution 
was perfused into the chamber. 
To measure membrane potentials and whole cell 
conductances, the nystatin performed patch technique was 
used under current clamp conditions. The pipette solution in 
these experiments consisted of (in mM): 12 NaC1; 64 KC1; 
28 &SO,; 47 sucrose; 1 MgC1,; 0.5 EGTA, 20 HEPES; 
titrated to 7.35 with KOH. Nystatin was added at a concen- 
tration of 300 pgiml to permeabilize the patch. Access 
resistances of e40 MQ were consistently achieved with this 
concentration of nystatin. Whole cell conductance measure- 
ments were made by pulsing 250 pA across the membrane. 
RESULTS 
10 
1s 
20 
2s 
30 
3s 
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We examined the effects of the antisense and sense 
oligonucleotides on the strain-induced increase in whole cell 
conductance in UMR-106.01 cells, which we have shown to 
be the result of upregulation of the stretch activated cation 
channel. A previous report had demonstrated that antisense 
oligonucleotides produce a time dependent inhibition of the 
chlorothiazide-induced increase in [ CaU”], in the mouse 
distal convoluted tudbule cells. This inhibition starts 6 hrs 
after introduction of the antisense and peaks at 18 hrs. The 
delay in inhibition was attributed to the turnover of existing 
proteins prior to the inhibition of new synthesis by the 
antisense. Cell conductance measurements of the strained 
UMR cells which had been transfected with the 24-mer 
antisense found a similar time dependence which began at 
12 hr. Measurements at 18 hr found 100% inhibition of the 
strain-induced increase in whole cell conductance (FIGS. 
4(a), 4(b)). Parallel time control cells which had been sham 
permeabilized exhibited no decrease in whole cell conduc- 
tance. A similar time course and inhibition was observed for 
the 20 mer antisense (FIGS. 5(A), 5(B)). Transfection of the 
sense oligonucleotide produced no significant changes in the 
whole cell conductance increases associated with hypotonic 
swelling (FIG. 6). Return of the whole cell conductance 
response to hypotonicity was observed 26 hr following 
introduction of the antisense oligonucleotides. This response 
was significantly higher than the control response, suggest- 
ing some feedback mechanism on the gene to increase 
expression of this protein. 
In view of the above, it will be seen that the several 
objects of the invention are achieved and other advantageous 
results attained. 
As various changes could be made in the above compo- 
sitions and methods without departing from the scope of the 
invention, it is intended that all matter contained in the 
above description shall be interpreted as illustrative and not 
in a limiting sense. 
SEQUENCE LISTING 
( 1 ) GENERAL INFORMATION 
( i i i ) NUMBER OF SEQUENCES: 17 
( 2 ) INFORMATION FOR SEQ ID NO:1: 
( i ) SEQUENCE CHARAnERISTICS: 
( A ) LENGTH 7860 base pairs 
( B ) TYPE: nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:1: 
C C C A A C A C C T  T A A T A T T T A T  A T C T C C A C G T  T G T T T T A T T T  T T T T T C C C C T  T G T T T T G G G G  
G G C T T T T A T T  T T C C T T T T G T  T T T T A A A A T T  T T A T C C T T G T  A T A T C A C A A T  A A T G G A A A G A  
A A G T T T A T A G  T G T C T T T C A C  A A A G G A G C G T  A G T T T A A A T G  C C C C G C C G C G  C C C G C G C C C G  
6 0  
1 2 0  
1 8 0  
2 4 0  C C C C T G C C A G  A A C G G C G C T C  G G C G G C G C G G  C C C G G A G C G G  C G G C G G C G G T  G G C G G C G G C G  
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-continued 
G C G G C C G T T C  
G T C G G G G C C T  
T C G G G G T C C A  
C T C G C T C T G C  
AGAGGTGCGG 
CACGAAAGGA 
CAGGTAATCA 
AGAGCCGCCG 
T T C C T C T T T G  
G G A T G T A C G T  
ATGCCAACAT 
G G G C A G C A C T  
GTGCTGGCAA 
GGAAACCCAA 
T G A C T C T G A A  
AAATAATTAT 
T T C C G G A A G A  
T C A T C A T T T T  
CCAACGCTTA 
T T T T T A G T G C  
AAGGAGCGGG 
T G G T G T C T G G  
CCCTGCTGCA 
T G G A G C T C T T  
T T C C A G C G G A  
AGAACGGGAC 
ACAACTTCGC 
ACGTGCTGTA 
G T C T G G T C A T  
AGTTTTCCAA 
AGCAGCAGCT 
T A G A C C C T G A  
CCACAAGTGA 
AAAACTGTGG 
GCCGGTGGAA 
ACTGGCTGGT 
ACCAGCCTCA 
T C A C G G C A G A  
T C T T C A A C C G  
AGACGAAGAT 
C C G C G G G C T C  
C G C G G C G A T C  
C C C G G C G C C G  
CTCTCCATTT 
T G C T A A A T T C  
G G C G G T A G T G  
C C C G A A G G A G  
G C C T C G G A G G  
T G G C T T C T C C  
T C C A G A G G A A  
G A A T G C C A A T  
G T C C T G G C A G  
T G C G A C C A T C  
G A A G C A G G G G  
G A A C C C C A T C  
T T T A T T G A C G  
T G A C T C C A A C  
T A C C G T G G A A  
C C T C C G C A A C  
A A T T T T A G A A  
A T T C G A T G T G  
AGTCCCAAGT 
C A T T G C C C T C  
C A T G G G G A A G  
A G A G G A T C C C  
C G T G T G C A A G  
C T T C G C C A T G  
CTGGATGCAA 
C T T T G G A T C C  
A G A G A G G G A G  
A G A A G A A G A T  
G A A T G A G G A C  
G A C T G A G T C T  
AGCCCGGCTT 
T A G A T T C T G C  
G A T C T T C C T G  
T T G G C T C A C A  
A A T G C T C C T G  
CTTTGACTGT 
C A T G T C G C C C  
G C C C T C A G G T  
G C C C T G G G C G  
CGGGCCCGCC 
A T T A T T A T T A  
T T G G A A G G G G  
G A A A G C A G C A  
C A A G A A C C A C  
AGGGATCCAT 
T T T C C A A G C A  
A A C C A C C A A G  
G C A G C T G C A G  
G C A G C C A T C G  
T C T A C C G T C A  
G G C A C A A C T G  
AGGAGGGCAT 
A T T T T T G C C A  
G C C A C C A A C T  
G C A T T T T T A A  
G G T T G G A A T T  
CAAGCAACCA 
A A G G C A C T G A  
C T C C A G G T G G  
CTCGTGCTCT 
A T G C A C A A G A  
T C C C C T T G T G  
C C C G G G T G G G  
CTGACGGTGT 
G A C G C T A T G G  
T T T T T C G T T C  
A A A G C C A A A G  
CTCAAAGGCT 
G A G G G C A T G G  
G T C A A C A C C G  
G C C C A C C G G A  
AGAAGAAAGT 
G T G T T C C T C A  
G A A G T G C A A G  
A A G A T G T A C A  
T T C A T T G T G T  
CTGGGCATCT 
G T T C G C G G C T  
G G C C G G A G A C  
G C T C T C C C T C  
T C A T T T T T G T  
CCCGGATGTA 
G T T T T T G G T G  
T G C G G A T C C A  
C C A G A G G C T C  
G T T T T T G G C C  
G T T C C A A C T A  
G A C T T G C C C C  
ATGCCGCCCG 
GTTCCACACA 
CCACACGGCC 
G C A T C A G C A T  
ATTGTGTGGC 
CCAACCTGGA 
AAGTGATTGC 
T A C T A G A T T T  
A A G C T G A C G G  
G A G C T T T C C G  
T C C T G A A C T C  
T C G T C A T C A T  
CCTGCTACAA 
C T T T G G A G A C  
A T G G G C C C A A  
T C C A G T G T A T  
G C T A T G A G T T  
T A A A T C T G G T  
CTCGAGGAGA 
A C C T G G A C T G  
A T G A A G A C A A  
AAAACGTGGC 
T C T C C A A A T C  
G C C G T G C C G C  
ACACCCTCAC 
A C A C G G C C A A  
G C C T G G G T C T  
G C G G G G G C A T  
C C G T G C T G A G  
G C C G T C G C C G  
G C C T C G G G C C  
G C C T C G C C T T  
T T T C A A A T G G  
C T G A G G A T G C  
T T T G G T G C A A  
C G G C T T C C T G  
G C G G G C T G T T  
AATGGTCAAT 
T G G G A G C C C A  
C G A G C A C A T C  
G C A G G C C A A G  
G C G G A A G C G G  
G C C C C G G G C T  
T G T T G A A T G G  
C T T A G C A A T C  
A C G G G T G G A G  
CTACGGACTA 
T A T A A T C G T G  
G G C C A A C G C T  
T G T G C T T C G T  
C A T C A T C A A G  
C A T C T A T G C C  
C C A G G A G G G C  
A G G C C A T G G G  
G C A C G G C A T C  
C A C C A T G G A G  
G C C C T G G G T G  
TCTCGGTGTT 
C T T C C A G A A G  
G A T C A C C C A G  
ACCCCGAAAC 
T G G A G G T G A C  
C A A G T T C A G C  
AGTTAAGTCC 
C A T T G C C T C C  
C A A G G C C C T C  
G C A G G C C T A C  
C C T G G A G A C C  
A T G T G T G C G G  
A A G A T C G C G G  
C C C T G G C G G C  
T G C G C C T C T T  
T G T A G C C G C C  
A T T A C A A T C T  
T A A T G G G G A T  
G A T T T G C G C G  
G C T G C A T T T C  
G A A A A C A C G A  
C G C C C A G C T C  
C C T A C T C C A G  
T T A A T G G G C A  
C A G C A G T A T G  
C T G C T C T G C C  
A A A C C A T T T G  
TATATTCCCT 
T A T C T C T T C C  
C T C T T C C A C C  
G T T G T A G G G C  
CTGGGAGGGA 
C C C C T G C G G C  
G C C A T G G T G C  
ATTATCGGCC 
A T A A T A G A T G  
C G A C A G T G T C  
A C C A A C T T C G  
G G C T G G A C A G  
T A T T T T G T C A  
T T G A G C G G A G  
CTTCGTGAGA 
G C G G A A G A C A  
A T G A G C A T G C  
A T C G A G G G T G  
C G C T A C T G G C  
AACGTCTTCT 
G A A C A C T A C A  
CTGGCCCTTT 
T T T G T A T C C C  
A T C C T G G T G G  
CTGCTCAGGA 
3 0 0  
3 6 0  
4 2 0  
4 8 0  
5 4 0  
6 0 0  
6 6 0  
7 2 0  
7 8 0  
8 4 0  
9 0 0  
9 6 0  
1 0 2 0  
1 0 8 0  
1 1 4 0  
1 2 0 0  
1 2 6 0  
1 3 2 0  
1 3 8 0  
1 4 4 0  
1 5 0 0  
1 5 6 0  
1 6 2 0  
1 6 8 0  
1 7 4 0  
1 8 0 0  
1 8 6 0  
1 9 2 0  
1 9 8 0  
2 0 4 0  
2 1 0 0  
2 1 6 0  
2 2 2 0  
2 2 8 0  
2 3 4 0  
2 4 0 0  
2 4 6 0  
2 5 2 0  
2 5 8 0  
2 6 4 0  
5,824,550 
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T T T T C A A G A T  
C A G T G C G C T C  
T C C T G G G G A T  
GCACGTTTGA 
ACTGGAATTC 
T G T T A G T C T G  
T G T T C T T G G C  
A A G A G G A A G A  
AACAGGAGGT 
AGTCCATTAC 
AGCCCAGTGA 
ATGAGGAGGA 
T T A A G G A A A A  
ACAGGTTCCG 
T C T T C T T C A T  
CCTTCAGGAA 
AAATTATCCT 
ATTACTTCAA 
AGTCCAGCGC 
GGGCCATCAA 
G G A C C A T T G G  
G G G T C C A G C T  
CAGAATGCAA 
AGCCTCGAAG 
C C C T C T T T A C  
CCCACACAGA 
T C A T C T A C A T  
T C A C C T T C C A  
G A C A A T G T G T  
AGCACCAGTA 
T C C T C A T C C T  
T C A A A A T C G C  
T C C T G A A G C T  
ACTTCCTCAT 
AACATACCCA 
T C T T C C G C C T  
G G A C C C T G C T  
T T G T G A T G C T  
T G A A T G A C A C  
T A C T G C T C T T  
C A C C A G G T A C  
C A T C G C C T C C  
G C A G C T G T T T  
T A A C T T C C C G  
G G T G A T G T A T  
T A T T T A C T T C  
C A T T G C G G T G  
A G A A G A G A A G  
G A T G G A G A A A  
A G C A G A T G G A  
A A A T G A G G A C  
G C C C G A G A T G  
G G C A G T C C C C  
C C T G C A G T G C  
TCTGCTCAGT 
CCACATCCTA 
TAAGATGACT 
T A T C C T G G A C  
G A T C A A C G T T  
C A G G G C C A A G  
A A A C A T T G T A  
CTTCAAGGGA 
G G G T A A C T A T  
T T G G G A G A A C  
C G T C T C C A C C  
A G A C A A G G G T  
CATCATCATT 
G G A G C A G G G G  
G G A A T A T G C C  
C A A A G T G T G G  
G C T C A A C A C C  
CATGAATATA 
C A T T G C C T T C  
C G T C A T T G G G  
A T G C T C T C C C  
C T T C C G G G T C  
G T G G A C C T T C  
G T T C T T T A T C  
C A C A G A G A T C  
C A G G T G C G C C  
T G G A A C T C C C  
CTGCTGCTAC 
G G T G G A A A G T  
CAGTCTCTCC 
G A T G G G A T C A  
ATCATCCTCT 
G A C A A C C T G G  
G A G A G A A A G A  
C C A G C A G T A G  
G A A T C C C C G C  
A A G A G T C C C C  
C C T G T G G G C C  
A T G C C G G A A G  
C A C C G C A T T G  
AGCATCTCCC 
G G C A A T G C A G  
G C T T A C G G G G  
C T G C T G G T G G  
G T G A A G A T T T  
G G G C T A A A G C  
A T T G T C A C C A  
A A G C T C T A T A  
A T A A C A T A C A  
A G C A A G T T C G  
T T C G A G G G G T  
CCCATCTACA 
G C C T T C T T C A  
G A A C A A G A A T  
C T C A A G G C C C  
T A C G T G G T C A  
A T C T G C C T G G  
C T C A A C A T G C  
A A A C C C A A G G  
A G C A T A A T T G  
T C T A T G A G T G  
A T G C G C C T G G  
ATCAAGTCCT 
T A T G C A G T G A  
A A T C G G A A C A  
A C T G G G G A G G  
T G A G C A A C C T  
TCCTCTTCCT 
T C A A C T T T G A  
T C A C T G T G T T  
T G G C T T A T G G  
T C A T C T G T G G  
C T G A T G C G G A  
A G C T G G C C A G  
A G G A G A G C A A  
CCACTACCAA 
ACTCCAACCC 
C A C G C C C C C G  
C C A G T G C A T T  
T C A A T G A C A C  
T G G C G G C T G A  
ACTATGTCTT 
CTTTCCTGCA 
T T A G C G T G T C  
T A A G A G T G C T  
A C G T C G T T C A  
C T C T G C T G C A  
CCTGTTCGGA 
A A G A C G G A G A  
A C T T T G A C A A  
G G C C A G A G C T  
ACTATCGTGT 
T G A T G A A C A T  
A C A A G A A C T G  
G A C C C T T G C G  
A C T C C A C C T A  
CCATGCAGCA 
T T T T C A C T G G  
G T T A C T T T A G  
ATGTCATTCT 
C A G A G G A G A A  
T G A A G C T G C T  
T C C A G G C C C T  
T T G G G A T G C A  
A C A A C T T C C A  
C C T G G C A G G A  
C G T G G C G T C C  
CTTCATCATC 
T G A G A T G C A G  
T C A G A T C C T G  
C G G C C C C T C T  
A A A T T A T A T C  
G A G C C T G A C C  
G A C T G C C A G C  
A G A G G A G A A A  
G A T C A A C A T G  
A G A C A C T G C A  
G C C C C T G T C T  
T T T C A T C T T C  
G A T C T T C A C C  
G G A C C C C G T C  
C A C T A G T A T C  
C A A G G G C T C T  
C C T C A T C T C C  
T C G T G T C C T C  
G T G T G T G T T T  
G T T C A T G T T C  
T A G T T C C A A A  
AGTTGACCAC 
T G T T C T G G C A  
G C T G T A C C G C  
G G A G A T C T C C  
CTTCGTGGGT 
T G A G C T G G A C  
A A G G T A C A T C  
C T T C G A G T A T  
C T A C G G C C A G  
C C T C T T C A C G  
T G A T C C C T G G  
C A G T G A A A C T  
C T C C C G C A T C  
G A G C C G A G G G  
G C C C T A T G T G  
G G T A T T T G G G  
G A C G T T C C C T  
T A T C A T G C T A  
T T G C T G A A C T  
ATCTTCTCCC 
A C C C G T A G G A  
A C C G G G G A G G  
T T T C C A G G G A  
C T A C T G A A T G  
T C T G C C C A A A  
CCAGAAAAGA 
ATTGAGCTGA 
G A T G A C C T C C  
G G T G A A G A G G  
G A G C T G C A C C  
A G C C C A A A C A  
AACCTCATCC 
CAGCACACCT 
T T T A C A T T A G  
T T C T G C C G A A  
T T T G G C A T T C  
A G G C C C C T G A  
G T G G C C A T C C  
G C C T G C A T T G  
C A G A C G G A G G  
C C C A T T A T C C  
G C C A T G A T G G  
T C C A T T G A C T  
A T C T T C T T C A  
T T C G T C A T T G  
A A G A A C C A G A  
C C C A A G A A C C  
C T G A T G T T C G  
AGCTGCCTCT 
G T G G A G A T G A  
A A T G T T T T T G  
A A T C C A G C T G  
T C C A T C A C C T  
G A A G G C A T C C  
G C C C T T T T G A  
A A G A T T G C C C  
C A G G C T G T G C  
G C C T G T A T G C  
2 7 0 0  
2 7 6 0  
2 8 2 0  
2 8 8 0  
2 9 4 0  
3 0 0 0  
3 0 6 0  
3 1 2 0  
3 1 8 0  
3 2 4 0  
3 3 0 0  
3 3 6 0  
3 4 2 0  
3 4 8 0  
3 5 4 0  
3 6 0 0  
3 6 6 0  
3 7 2 0  
3 7 8 0  
3 8 4 0  
3 9 0 0  
3 9 6 0  
4 0 2 0  
4 0 8 0  
4 1 4 0  
4 2 0 0  
4 2 6 0  
4 3 2 0  
4 3 8 0  
4 4 4 0  
4 5 0 0  
4 5 6 0  
4 6 2 0  
4 6 8 0  
4 7 4 0  
4 8 0 0  
4 8 6 0  
4 9 2 0  
4 9 8 0  
5 0 4 0  
5,824,550 
24 
-continued 
CAGGCAAGAA 
G T G G C A G C A G  
T C A T C A A C C T  
C T A T C C T T G G  
AAGCCAAGGG 
C A C T G G G T T T  
ACATGCCTCT 
G G A C A G C C C T  
CCATCATCAA 
CTGCAGGTGA 
ACTTCAGGAA 
ATGCACTGTC 
G A G C C A T C T C  
T G T C T G C T G C  
T C A G C T A C T A  
C A C T G C A C A T  
AGCTGGTGGA 
T C A A C A A T G C  
C G G T C A G C A C  
CAGCATGGAA 
G T C A G G A T A T  
ACTGCAGTGA 
G A C A A C T G A C  
T C C T T C G C T C  
AAAAGGATCA 
ACCAGGCATT 
C G T T T C C C A G  
AGCCCATCCC 
T C C C G T C C A T  
G C A T G G C C C G  
G C A G A C A G T T  
T G G G A C A G T T  
C C T G C G A T A T  
C C C A G C A G A G  
ACAGGGCTGT 
AGGAAGCGCT 
G A C G C G G G T G  
C T G T T C T C G T  
C C T C A G A G C T  
C G G G G G C T C C  
G T G T G C T C C A  
T T T C G C T G T C  
CTTTGTAGCT 
T C C C C A T C A C  
T C G G A T C A A A  
T G G G A A G T T G  
G A A C A G T G A T  
G A G G A T C A A A  
G A A A A T C T G G  
T G A C G A G G T C  
A T T C A A G A A G  
TCTGCAGGCT 
T G G G G A T C T G  
C T C C G A A G A C  
C C A G A G T G A C  
CAACAAGACA 
C T C C A C T T T C  
CAACAACACT 
T G T G G A G G G C  
ACTCAGCTCT 
G T T T C C A G A T  
G C C C A G C C T G  
C T G T C T A G A G  
T G C C T C T C T A  
A G G A G G A G A C  
G G C A G T G G C A  
G C C A C G C C C C  
T A C C C T G C G G  
C C A C T G C A G C  
G A G A G C C C G G  
C C A C G G C A G C  
TGCTCAAGAT 
G A C A A T A G A G  
C C C C A A C G G C  
G G T C C C A G A G  
C C C G G A C A G C  
T T T T T T A T T C  
G A C C T G G A G G  
G G G C G G T G T A  
A G C A C C T T C C  
G A G T C T G A G C  
T T C T A C T T C A  
G T T A T C A T G G  
CTGGATGAAT 
C A C T T G G A T G  
T G T C C T C A C C  
G G G A C G G T C A  
A C A G A A G G G A  
A A G A G G A C C A  
A C A G T G G G C A  
C G A A A A G A G C  
G G C T T A C G C A  
A C G G C T G A G G  
G A C A T C T T C A  
A G C A G G A G C A  
G G G A A C A A C C  
A C C C C C A G C A  
G C C C T G G G C C  
C A T G G G C C T C  
A A G A G G T G C C  
G A G A C C C G C A  
C T C T C C A C A G  
G A G G A C A A G A  
G G T C G A A G G G  
A T C T C T C A G A  
G G C T T G A G C C  
A C G C C C C C T G  
C T G G A G G G G G  
T C C T G G T C A G  
CCCGTCTCCC 
G C C A G C A G C C  
CCCAAGTTCA 
G A G A T G G A G A  
ACCCTCTTAC 
G A C G A G A G C T  
A G G T C C T A T G  
G T T T C A A T G T  
T A A C C G G A A C  
C G A A G T C G G C  
CACGGCAGCA 
C C A G C A A C A G  
T C A G C T T C T A  
ACAACTTTGA 
T C A A G A G A A T  
T G G T G A C C C T  
G T G T G G C C T G  
T G T T C A A T G C  
A C C T A G A G C A  
G C A T G A A G C T  
AGTTCTATGC 
AGGGGCTGGT 
CCTTGCATGA 
A G G A G C T G G A  
G G A G G G C T G G  
ACTTCCCTCA 
AAGCGGACAC 
G C T A C T C A T C  
GCTTCCCCCA 
C C T T G T C C C C  
A C T C C C G A G A  
G C A G C G T G A G  
ATATACTCTC 
G G G A G A T C C A  
CCTCCTTCCA 
AGACAGCCTT 
CCCTCCTGCA 
T C A C T C C A G G  
C G G A G T C C A G  
AGGAGACCAC 
T C A C C G T G C C  
T G G T G G A A G C  
T C G A G G T C A C  
A C G C C G C A G A  
CTTTTGTGAA 
G T G T A T A T G C  
T C A G C A A C C T  
T C C T A A T G G G  
AGCGTCTTCA 
T T T T C A G G G G  
C C G C C C A A A G  
C A C G G A A G G G  
CATGCTCTGT 
CTACCTGACT 
CTGGGCCGAA 
CCTCCGTCGA 
C A A A C G C C T G  
T A C A C T G T T T  
AGCCAATGAG 
G T T G G A C C A G  
C A C C T T C C T G  
C G G C A A G C C C  
C A T T G G G C C T  
C A A G G C T A T G  
A G G C C T G T T T  
G A C G T T T G C C  
C G A A T C A C C G  
C A C G G G C T C C  
C C C T G C T G G C  
T G C T G T C C G G  
G A G C C A G G G G  
GCTGAGCGAA 
C T A C C A G G A C  
G C C A T C T C C G  
T C T G G A A T G T  
G C C C T T G C A T  
G A G A A G C C A T  
C A G C C G G G G C  
T G A G A A A C T C  
AGCCTGTAGT 
CAGCCAGGCT 
G G T C T T G A T T  
C A C A C A G G A G  
C A A C A T C C T C  
C T G C A G G G A C  
CCTGGGGCGA 
G T A G T C C G C A  
T T C G T T T C A G  
T T C A C T G C T G  
AGAAGGCCAA 
G A C C C C A C C C  
G A G A C A C C C T  
G C C T T C C T G A  
AGGGATTGGT 
T A T G A C C C T G  
A T T C A G C C C C  
G T G T C C A T G A  
G C C C T T G T C A  
G A G C T G A G A G  
G T G G T G C C C C  
ATCCAAGAGT 
T C G C A G A G G A  
G A G A T C C G G A  
A A G G A G G C A G  
G G C A A C C A C G  
A C C C A A C G C C  
T C C C A T G A G A  
A A T G C C A A C A  
T A C T C C A G C A  
G T A C A G G A G G  
G C C A C G G T G A  
G A A G T T G A G T  
G A T G A A A A C C  
AAGAGGAGTT 
CTAAAGCGAC 
C T G G T T C A T C  
T C T C C T T C C A  
AGGCCCCTAC 
AACAGCAGCT 
G G G G G C A G C A  
G G A G C T C C A G  
T C A G A A G G A C  
C T G G C T G A C G  
A G C G G G G G C G  
C C A G G G C A G G  
G G C C A G A G C G  
G G G C T G G C G A  
A A G T G C C T C A  
T C G G G A T A A G  
G G C C G T G G T G  
CCCCTAAGCA 
5 1 0 0  
5 1 6 0  
5 2 2 0  
5 2 8 0  
5 3 4 0  
5 4 0 0  
5 4 6 0  
5 5 2 0  
5 5 8 0  
5 6 4 0  
5 7 0 0  
5 7 6 0  
5 8 2 0  
5 8 8 0  
5 9 4 0  
6 0 0 0  
6 0 6 0  
6 1 2 0  
6 1 8 0  
6 2 4 0  
6 3 0 0  
6 3 6 0  
6 4 2 0  
6 4 8 0  
6 5 4 0  
6 6 0 0  
6 6 6 0  
6 7 2 0  
6 7 8 0  
6 8 4 0  
6 9 0 0  
6 9 6 0  
7 0 2 0  
7 0 8 0  
7 1 4 0  
7 2 0 0  
7 2 6 0  
7 3 2 0  
7 3 8 0  
7 4 4 0  
5,824,550 
26 
-continued 
AAAGGGTGTT TTCCCCTTGC TTGTATAAAC AGTCATTTGC ACATGTTCTG TCTGAGCCTG 
GCCGTCTCTA TGGAGCAGGG CCCCAGGGAT CTATGGCAGG AATGGCCAGT GTCCCCAGTA 
GGAGCCGGAA GGTGGCTGCA AGGTTCCCAG CAGTGCAGAT CTGGTCCCTA TTGCCCTTCA 
GGGACCCTTC CCCTGCTGGA ACTGAGGAGC AGGTGCAGGA GCCAGTGCAG ACCACACCAC 
CTGCCCTCAG CTAGCCAGAC CTGGGGGCGC AGGCTGCTTG CCTGGTGCTC TGGGTTTCAT 
AGTTTGATGG TTCTTGTCAG CATGTTGCGG TTTTCTAGGT TTTGATTTCT TTATTACTAT 
TTGTTGTGTT TTCCCACGGG GAGGGGAGGA AGAAGAGCGT TTACAACTGC GCAGCTCACG 
( 2 ) INFORMATION FOR SEQ ID NO2 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 24 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:2: 
CCTTCCGTGC TGTTGCTGGG CTCA 
( 2 ) INFORMATION FOR SEQ ID NO:3: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 20 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:3: 
ACTCTGGAGC ACACTTCTTG 
( 2 ) INFORMATION FOR SEQ ID NO:4 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 844 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:4: 
GGGGGAGACT GAGTATAAGA ACTGTGAGCT GGACAAGAAC CAGCGCCAAT GTGTGCAGTA 
TGCCCTGAAG GCCCGCCCGC TGAGGTGTTA CATCCCCAAA AACCCATACC AGTATCAGGT 
GTGGTATGTC GTCACTTCCT CCTACTTTGA ATACCTGATG TTTGCTCTCA TCATGCTCAA 
CACTATCTGC CTAGGCATGC AGCATTACAA CCAGTCGGAA CAGATGAACC ACATCTCGGA 
CATCCTCAAT GTGGCTTTCA CCATCATCTT CACCCTGGAG ATGATCCTCA AGCTCATAGC 
TTTCAAGCCC AGGGGCTATT TTGGAGACCC CTGGAACGTG TTTGACTTTC TAATCGTCAT 
TGGCAGCATC ATTGACGTTA TCCTGAGTGA GATCGATGAC CCAGATGAGA GCGCCCGCAT 
CTCCAGTGCC TTCTTCCGCC TGTTCCGAGT CATGCGACTG ATCAAGCTGC TGAGCCGGGC 
GGAGGGTGTG CGCACCCTGC TCTGGACGTT CACCAAGTCC TTCCAGGCCC TGCCGTATGT 
GGCTTTGCTG ATCGTCATGC TCTTCTTCAT CTACGCTGTC ATCGGCATGC AGATGTTCGG 
GAAGATCGCC ATGGTGGACG GGACGCAAAT AAACCGGAAC AACAACTTCC AGACTTTCCC 
ACAAGCTGTG CTGCTGCTCT TCAGGTGTGC CACAGGGGCA GCCTGGCAGG AGATCCTGCT 
GGCCTGCAGC TACGGGAAAC GCTGCGACCC GGAGTCTGAC TACGCACCGG GGGAGGAGTA 
CGCGTGTGGC ACCAACTTTG CCTACTACTA CTTCATCAGC TTCTACATGC TCTGCGCCTT 
7500 
7560 
7620 
7680 
7740 
7800 
7860 
24 
20 
60 
120 
1 8 0  
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
5,824,550 
28 
-continued 
CCTG 
( 2 ) INFORMATION FOR SEQ ID NO5 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 850 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO5: 
GGGGGAACAA GAATACAAGA ACTGTGAGCT GGACAAGAAC CAGAGACAAT GTGTGGAATA 
TGCCCTCAAG GCCCGACCCT TGCGAAGGTA CATCCCCAAG AACCAGCACC AGTACAAAGT 
GTGGTACGTG GTCAACTCCA CCTACTTCGA GTATCTGATG TTCGTCCTCA TCCTGCTCAA 
CACCATCTGC CTGGCCATGC AGCACTACGG CCAGAGCTGC CTCTTCAAAA TCGCCATGAA 
TATACTCAAC ATGCTTTTCA CTGGCCTCTT CACGGTGGAG ATGATCCTGA AGCTCATTGC 
CTTCAAACCC AAGGGTTACT TTAGTGATCC CTGGAATGTT TTTGACTTCC TCATCGTCAT 
TGGGAGCATA ATTGATGTCA TTCTCAGTGA AACTAATAGT GCAGAGGAGA ACTCCCGCAT 
CTCCATCACC TTCTTCCGCC TCTTCCGGGT CATGCGCCTG GTGAAGCTGC TGAGCCGAGG 
GGAAGGCATC CGGACCCTGC TGTGGACCTT CATCAAGTCC TTCCAGGCCC TGCCCTATGT 
GGCCCTTTTG ATTGTGATGC TGTTCTTTAT CTATGCAGTG ATTGGGATGC AGGTATTTGG 
GAAGATTGCC CTGAATGACA CCACAGAGAT CAATCGGAAC AACAACTTCC AGACGTTCCC 
TCAGGCTGTG CTACTGCTCT TCAGGTGCGC CACTGGGGAG GCCTGGCAGG ATATCATGCT 
AGCCTGTATG CCAGGCAAGA AGTGTGCTCC AGAGTCTGAG CCCAGCAACA GCACGGAAGG 
GGAGACACCC TGTGGCAGCA GTTTCGCTGT CTTCTACTTC ATCAGCTTCT ACATGCTCTG 
TGCCTTCCTG 
( 2 ) INFORMATION FOR SEQ ID NO:6: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 844 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:6: 
GGGAGAAAAG GAGTATAAGA ACTGTGAGCT GGACAAAAAT CAGCGTCAGT GTGTGGAATA 
TGCCTTGAAG GCCCGCCCCT TAAGGAGATA CATCCCCAAA AACCCATACC AGTACAAGTT 
CTGGTACGTG GTGAACTCCT CGCCTTTCGA ATATATGATG TTTGTCCTCA TCATGCTCAA 
CACGCTCTGC CTGGCCATGC AGCACTATGA GCAATCCAAG ATGTTCAATG ACGCCATGGA 
CATTCTGAAC ATGGTCTTCA CGGGGGTCTT CACCGTTGAG ATGGTTTTGA AAGTCATCGC 
ATTTAAGCCC AAGGGGTATT TTAGTGACGC CTGGAACACG TTTGACTCCC TCATCGTAAT 
CGGCAGCATT ATAGACGTGG CACTCAGCGA AGCTGACAAC TCTGAAGAGA GCAATAGAAT 
CTCCATCACC TTTTTCCGTC TTTTCCGAGT GATGCGGTTG GTGAAGCTTC TCAGCAGAGG 
GGAAGGCATC CGGACTCTGC TATGGACCTT CATTAAGTCC TTCCAGGCAC TCCCATATGT 
CGCCCTCCTC ATTGCCATGC TCTTCTTCAT CTACGCCGTC ATTGGCATGC AGATGTTTGG 
GAAGGTTGCC ATGAGAGATA ACAACCAGAT CAATAGGAAC AACAACTTCC AGACGTTTCC 
CCAGGCAGTG CTGCTGCTCT TCAGGTGTGC AACAGGGGAG GCCCGGCAGG AGATCATGCT 
CGCCTGCCTC CCTGGGAAGC TGTGTGACCC GGACTCAGAT TACAACCCAG GAGAGGAATA 
8 4 4  
60 
1 2 0  
1 8 0  
2 4 0  
300 
360 
4 2 0  
4 8 0  
5 4 0  
600 
660 
7 2 0  
7 8 0  
8 4 0  
8 5 0  
60 
1 2 0  
1 8 0  
2 4 0  
300 
360 
4 2 0  
4 8 0  
5 4 0  
600 
660 
7 2 0  
7 8 0  
5,824,550 
-continued 
T A C T T G T G G G  A G C A A C T T T G  C C A T T G T C T A  C T T C A T C A G C  T T T T A C A T G C  T C T G C G C G T T  8 4 0  
C C T G  8 4 4  
( 2 ) INFORMATION FOR SEQ ID NO:T 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 51 amino acid residues 
( B ) TYPE amino acid 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:7: 
P r o  T r p  A s n  V a l  P h e  A s p  P h e  L e u  I l e  V a l  I l e  G l y  S e r  I l e  I l e  A s p  
1 5 1 0  1 5  
V a l  I l e  L e u  S e r  G l u  I l e  A s p  A s p  P r o  A s p  G l u  S e r  A l a  A r g  I l e  S e r  
2 0  2 5  3 0  
S e r  A l a  P h e  P h e  A r g  L e u  P h e  A r g  V a l  Met A r g  L e u  I l e  L y s  L e u  L e u  
3 5  4 0  4 5  
S e r  A r g  A l a  
5 0  
( 2 ) INFORMATION FOR SEQ ID NO:8 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 70 amino acid residues 
( B ) TYPE amino acid 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NOS: 
P r o  T r p  A s n  V a l  P h e  A s p  P h e  L e u  I l e  V a l  I l e  G l y  S e r  I l e  I l e  A s p  
1 5 1 0  1 5  
V a l  I l e  L e u  S e r  G l u  I l e  A s p  T h r  P h e  L e u  A l a  S e r  S e r  G l y  G l y  L e u  
2 0  2 5  3 0  
T y r  C y s  L e u  G l y  G l y  G l y  C y s  G l y  A s n  V a l  A s p  P r o  A s p  G l u  S e r  A l a  
3 5  4 0  4 5  
A r g  I l e  S e r  S e r  A l a  P h e  P h e  A r g  L e u  P h e  A r g  V a l  Met A r g  L e u  I l e  
5 0  5 5  6 0  
L y s  L e u  L e u  S e r  A r g  A l a  
6 5  7 0  
( 2 ) INFORMATION FOR SEQ ID NO:9: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 51 amino acid residues 
( B ) TYPE amino acid 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:9: 
P r o  T r p  A s n  V a l  P h e  A s p  P h e  L e u  I l e  V a l  I l e  G l y  S e r  I l e  I l e  A s p  
1 5 1 0  1 5  
V a l  I l e  L e u  S e r  G l u  T h r  A s n  S e r  A l a  G l u  G l u  A s n  S e r  A r g  I l e  S e r  
2 0  2 5  3 0  
I l e  T h r  P h e  P h e  A r g  L e u  P h e  A r g  V a l  Met A r g  L e u  V a l  L y s  L e u  L e u  
3 5  4 0  4 5  
S e r  A r g  G l y  
5 0  
( 2 ) INFORMATION FOR SEQ ID NO:10: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 62 amino acid residues 
( B ) TYPE amino acid 
( D ) TOPOLOGY linear 
5,824,550 
32 
-continued 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:lO 
P r o  T r p  A s n  V a l  P h e  A s p  P h e  L e u  I l e  V a l  I l e  G l y  S e r  I l e  I l e  A s p  
1 5 1 0  1 5  
V a l  I l e  L e u  S e r  G l u  T h r  A s n  P r o  A l a  G l u  H i s  T h r  G l n  C y s  S e r  P r o  
2 0  2 5  3 0  
S e r  Met S e r  A l a  G l u  G l u  A s n  S e r  A r g  I l e  S e r  I l e  T h r  P h e  P h e  A r g  
3 5  4 0  4 5  
L e u  P h e  A r g  V a l  Met A r g  L e u  V a l  L y s  L e u  L e u  S e r  A r g  G l g  
5 0  5 5  6 0  
( 2 ) INFORMATION FOR SEQ ID N0:l l :  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 51 amino acids 
( B ) TYPE amino acid 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID N0:l l :  
A l a  T r p  A s n  T h r  P h e  A s p  S e r  L e u  I l e  V a l  I l e  G l y  S e r  I l e  I l e  A s p  
1 5 1 0  1 5  
V a l  A l a  L e u  S e r  G l u  A l a  A s p  A s n  S e r  G l u  G l u  S e r  A s n  A r g  I l e  S e r  
2 0  2 5  3 0  
I l e  T h r  P h e  P h e  A r g  L e u  P h e  A r g  V a l  Met A r g  L e u  V a l  L y s  L e u  L e u  
3 5  4 0  4 5  
S e r  A r g  G l y  
5 0  
( 2 ) INFORMATION FOR SEQ ID NO:12: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 66 amino acid residues 
( B ) TYPE amino acid 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:12: 
A l a  T r p  A s n  T h r  P h e  A s p  S e r  L e u  I l e  V a l  I l e  G l y  S e r  I l e  I l e  A s p  
1 5 1 0  1 5  
V a l  A l a  L e u  S e r  G l u  A l a  A s p  P r o  S e r  A s p  S e r  G l u  A s n  I l e  P r o  L e u  
2 0  2 5  3 0  
P r o  T h r  A l a  T h r  P r o  G l y  A s n  S e r  G l u  G l u  S e r  A s n  A r g  I l e  S e r  I l e  
3 5  4 0  4 5  
T h r  P h e  P h e  A r g  L e u  P h e  A r g  V a l  Met A r g  L e u  V a l  L y s  L e u  L e u  S e r  
5 0  5 5  6 0  
A r g  G l y  
6 5  
( 2 ) INFORMATION FOR SEQ ID NO:13: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 29 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:13: 
G C C G G A T C C A  T C G T C A C C T T  C C A G G A G C A  2 9  
( 2 ) INFORMATION FOR SEQ ID NO:14: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 29 base pairs 
5,824,550 
33 34 
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( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:14 
A T G G A A T T C G  C C A C R A A G A G  G T T G A T G A T  
( 2 ) INFORMATION FOR SEQ ID N0:lS: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 30 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID N0:lS: 
G T G G G A A T T C  A T C A A G T C C T  T C C A G G C C C T  
( 2 ) INFORMATION FOR SEQ ID NO:16: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 30 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:16: 
C A G G G G A T C C  A A G T T G T C C A  T G A T A A C A G C  
( 2 ) INFORMATION FOR SEQ ID NO:17: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 29 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:17: 
C C C G A A T T C A  K M G T G T T G A G  C A T G A T G A G  
2 9  
3 0  
3 0  
2 9  
What is claimed is: 
1. An antisense oligonucleotide that hybridizes with a 
region of a voltage-gated calcium channel a1 subunit mRNA 
and inhibits strain-induced increase in whole cell conduc- 45 
tance in osteoblasts, having a sequence selected from the 
group consisting of SEQ ID NO:2 and SEQ ID NO:3. 
2. The antisense oligonucleotide of claim 1, which is 
DNA. 
8. A method of inhibiting expression of a voltage-gated 
calcium channel a1 subunit gene in a cell, the method 
comprising the steps of  
(a) obtaining an antisense oligonucleotide that hybridizes 
with a region of a voltage-gated calcium channel a1 
subunit mRNA and inhibits expression of said a1 
subunit, having a sequence selected from the group 
consisting of SEQ ID NO:2 and SEQ ID NO:3, 
3. The antisense oligonucleotide of claim 1 in which at 50 (b) combining said antisense oligonucleotide with a phar- 
least one of the internucleotide linkages is a phosphorothio- maceutically acceptable carrier to create a pharmaceu- 
ate phosphodiester. tically active mixture, and 
4. The antisense oligonucleotide of claim 1 further char- (c) contacting said voltage-gated calcium channel a1 
acterized in that it does not hybridize with a CaChl or subunit mRNA within said cell in vitro with said 
CaCh3 mRNA. ss pharmaceutically active mixture, thereby inhibiting 
5. A pharmaceutical composition comprising at least one expression of said voltage-gated calcium channel a1 
antisense oligonucleotide that hybridizes with a region of a subunit gene within said cell. 
voltage-gated calcium channel a1 subunit mRNA and inhib- 9. The method of claim 8, wherein said cell is an osteo- 
its strain-induced increase in whole cell conductance in blast or an endothelial cell. 
osteoblasts, having a sequence selected from the group 60 10. A method of inhibiting expression of a voltage-gated 
consisting of SEQ ID NO:2 and SEQ ID NO:3, and a calcium channel a1 subunit in a cell, comprising contacting 
pharmaceutically acceptable carrier. said cell in vitro with an oligonucleotide having the 
6. The pharmaceutical composition of claim 5, wherein sequence shown in SEQ ID NO:2 or SEQ ID NO:3. 
the antisense oligonucleotide is DNA. 11. The method of claim 10, wherein said cell is an 
7. The pharmaceutical composition of claim 5,  wherein at 65 osteoblast or an endothelial cell. 
least one of the internucleotide linkages is a phosphorothio- 
ate phosphodiester. * * * * *  
